These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 15100107)

  • 1. False-negative findings for primary lung tumors on FDG positron emission tomography: staging and prognostic implications.
    Cheran SK; Nielsen ND; Patz EF
    AJR Am J Roentgenol; 2004 May; 182(5):1129-32. PubMed ID: 15100107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules.
    Daniels CE; Lowe VJ; Aubry MC; Allen MS; Jett JR
    Chest; 2007 Jan; 131(1):255-60. PubMed ID: 17218584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The maximum standardized uptake values on integrated FDG-PET/CT is useful in differentiating benign from malignant pulmonary nodules.
    Bryant AS; Cerfolio RJ
    Ann Thorac Surg; 2006 Sep; 82(3):1016-20. PubMed ID: 16928527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of occult metastatic disease in patients undergoing 18F-FDG PET for primary diagnosis or staging of lung carcinoma and solitary pulmonary nodules.
    Lee ST; Berlangieri SU; Poon AM; Mitchell P; Pathmaraj K; Tabone K; Byrne AJ; O'Keefe GJ; Knight SR; Clarke CP; Scott AM
    Intern Med J; 2007 Nov; 37(11):753-9. PubMed ID: 17517082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of [18F]FDG-PET imaging in small cell lung cancer.
    Pandit N; Gonen M; Krug L; Larson SM
    Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):78-84. PubMed ID: 12483413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings.
    Frank A; Lefkowitz D; Jaeger S; Gobar L; Sunderland J; Gupta N; Scott W; Mailliard J; Lynch H; Bishop J
    Int J Radiat Oncol Biol Phys; 1995 Jul; 32(5):1495-512. PubMed ID: 7635795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer?
    Aquino SL; Fischman AJ
    Chest; 2004 Sep; 126(3):755-60. PubMed ID: 15364753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging.
    Shim SS; Lee KS; Kim BT; Chung MJ; Lee EJ; Han J; Choi JY; Kwon OJ; Shim YM; Kim S
    Radiology; 2005 Sep; 236(3):1011-9. PubMed ID: 16014441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [18F] 3-deoxy-3'-fluorothymidine positron emission tomography: alternative or diagnostic adjunct to 2-[18f]-fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions?
    Halter G; Buck AK; Schirrmeister H; Wurziger I; Liewald F; Glatting G; Neumaier B; Sunder-Plassmann L; Reske SN; Hetzel M
    J Thorac Cardiovasc Surg; 2004 Apr; 127(4):1093-9. PubMed ID: 15052207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-fluorodeoxyglucose positron emission tomography in small-cell lung cancer.
    Zhao DS; Valdivia AY; Li Y; Blaufox MD
    Semin Nucl Med; 2002 Oct; 32(4):272-5. PubMed ID: 12524651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma.
    Hellwig D; Graeter TP; Ukena D; Georg T; Kirsch CM; Schäfers HJ
    J Thorac Cardiovasc Surg; 2004 Dec; 128(6):892-9. PubMed ID: 15573074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma.
    Hoang JK; Hoagland LF; Coleman RE; Coan AD; Herndon JE; Patz EF
    J Clin Oncol; 2008 Mar; 26(9):1459-64. PubMed ID: 18349396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of [(18)F]FDG PET and (201)Tl SPECT in evaluation of pulmonary nodules.
    Higashi K; Ueda Y; Sakuma T; Seki H; Oguchi M; Taniguchi M; Taki S; Tonami H; Katsuda S; Yamamoto I
    J Nucl Med; 2001 Oct; 42(10):1489-96. PubMed ID: 11585862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Occult lung infarction may induce false interpretation of 18F-FDG PET in primary staging of pulmonary malignancies.
    Kamel EM; McKee TA; Calcagni ML; Schmidt S; Markl S; Castaldo S; Delaloye AB
    Eur J Nucl Med Mol Imaging; 2005 Jun; 32(6):641-6. PubMed ID: 15726357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of F-18 fluorodeoxyglucose (FDG) PET scanning for pulmonary nodules less than 3 cm in diameter, with special reference to the CT images.
    Nomori H; Watanabe K; Ohtsuka T; Naruke T; Suemasu K; Uno K
    Lung Cancer; 2004 Jul; 45(1):19-27. PubMed ID: 15196730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease.
    Farrell MA; McAdams HP; Herndon JE; Patz EF
    Radiology; 2000 Jun; 215(3):886-90. PubMed ID: 10831716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pitfalls in lymph node staging with positron emission tomography in non-small cell lung cancer patients.
    Takamochi K; Yoshida J; Murakami K; Niho S; Ishii G; Nishimura M; Nishiwaki Y; Suzuki K; Nagai K
    Lung Cancer; 2005 Feb; 47(2):235-42. PubMed ID: 15639722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorodeoxyglucose positron emission tomography in pulmonary carcinoid tumors.
    Gasparri R; Rezende GC; Fazio N; Maisonneuve P; Brambilla D; Travaini LL; Paganelli G; Petrella F; Galetta D; Spaggiari L
    Q J Nucl Med Mol Imaging; 2015 Dec; 59(4):446-54. PubMed ID: 26416036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma.
    Ahuja V; Coleman RE; Herndon J; Patz EF
    Cancer; 1998 Sep; 83(5):918-24. PubMed ID: 9731895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
    Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
    Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.